For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.
The Union Minister for Chemicals & Fertilizers and Parliamentary Affairs Sh. Ananth Kumar has said that Promotion and Regulation should go hand in hand for medical devices sector to provide affordable health care to the poor. Speaking at the 9th Medical Technology Conference in New Delhi today he said that regulation is required in the medical devices sector to check profit and money making so as to facilitate providing adequate medical facilities to the poor.
Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of ofatumumab (Arzerra®) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which received Priority Review in May 2016, was submitted to the FDA by Novartis under the ofatumumab collaboration between Novartis and Genmab.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
